Literature DB >> 27209497

Higher β-HCG concentrations and higher birthweights ensue from single vitrified embryo transfers.

Kevin N Keane1, Kamarul Bahyah Mustafa2, Peter Hinchliffe3, Jason Conceicao3, John L Yovich4.   

Abstract

To examine the effect of cryopreservation on developmental potential of human embryos, this study compared quantitative β-HCG concentrations at pregnancy test after IVF-fresh embryo transfer (IVF-ET) with those arising after frozen embryo transfer (FET). It also tracked outcomes of singleton pregnancies resulting from single-embryo transfers that resulted in singleton live births (n = 869; with 417 derived from IVF-ET and 452 from FET). The initial serum β-HCG concentration indicating successful implantation was measured along with the birthweight of the ensuing infants. With testing at equivalent luteal phase lengths, the median pregnancy test β-HCG was significantly higher following FET compared with fresh IVF-ET (844.5 IU/l versus 369 IU/l; P < 0.001). Despite no significant difference in the average period of gestation (38 weeks 5 days for both groups), the mean birthweight of infants born following FET was significantly heavier by 161 g (3370 g versus 3209 g; P < 0.001). Furthermore, more infants exceeded 4000 g (P < 0.001) for FET although there was no significant difference for the macrosomic category (≥4500 g). We concluded that FET programme embryos lead to infants with equivalent (if not better) developmental potential compared with IVF-ET, demonstrated by higher pregnancy β-HCG concentrations and ensuing birthweights.
Copyright © 2016 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  FET; IVF-ET; birthweight; single embryo transfer; vitrification; β-HCG

Mesh:

Substances:

Year:  2016        PMID: 27209497     DOI: 10.1016/j.rbmo.2016.04.014

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

1.  Mosaic embryo transfer after oocyte in vitro maturation in combination with non-invasive prenatal testing (NIPT)-first report of a euploid live birth.

Authors:  Naomi Inoue; Rosmary Lopez; Andrea Delgado; Denisse Nuñez; Jimmy Portella; Luis Noriega-Hoces; Luis Guzmán
Journal:  J Assist Reprod Genet       Date:  2017-06-24       Impact factor: 3.412

2.  Maternal serum levels of angiogenic markers and markers of placentation in pregnancies conceived with fresh and vitrified-warmed blastocyst transfer.

Authors:  Milan Reljič; Admir Porović
Journal:  J Assist Reprod Genet       Date:  2019-05-18       Impact factor: 3.412

3.  Effect of frozen/thawed embryo transfer on birthweight, macrosomia, and low birthweight rates in US singleton infants.

Authors:  Julia F Litzky; Sheree L Boulet; Navid Esfandiari; Yujia Zhang; Dmitry M Kissin; Regan N Theiler; Carmen J Marsit
Journal:  Am J Obstet Gynecol       Date:  2017-12-29       Impact factor: 8.661

4.  Predictive value of initial serum human chorionic gonadotropin levels for pregnancies after single fresh and frozen blastocyst transfer.

Authors:  Wei-E Zhao; Yu-Jie Li; Jian-Ping Ou; Peng Sun; Wen-Qiu Chen; Xiao-Yan Liang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2017-06-06

5.  Association between infertility treatment and intrauterine growth: a multilevel analysis in a retrospective cohort study.

Authors:  Satoshi Shinohara; Shuji Hirata; Kohta Suzuki
Journal:  BMJ Open       Date:  2020-04-28       Impact factor: 2.692

6.  Live birth outcomes of vitrified embryos generated under growth hormone stimulation are improved for women categorized as poor-prognosis.

Authors:  Kevin N Keane; Yun Ye; Peter M Hinchliffe; Sheena Lp Regan; Satvinder S Dhaliwal; John L Yovich
Journal:  Clin Exp Reprod Med       Date:  2019-11-19

7.  Impact of mode of conception on early pregnancy human chorionic gonadotropin rise and birth weight.

Authors:  Hayley Richardson; Charikleia Kalliora; Monica Mainigi; Christos Coutifaris; Mary D Sammel; Suneeta Senapati
Journal:  F S Rep       Date:  2021-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.